Literature DB >> 6603303

Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis.

W W Shih, R W Baumhefner, W W Tourtellotte, C M Haskell, E L Korn, J L Fahey.   

Abstract

Cyclophosphamide (CY), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-fluorouracil (5-FU) were given in single course schedules to chronic progressive multiple sclerosis (MS) patients clinically stable for 6 months. The following peripheral immune cellular parameters were measured before, during and after each drug administration: white blood count (WBC), polymorphonuclear count (PMN), lymphocyte count, percentage of T cells, T cell response to phytohaemagglutinin (PHA), percentage of B cells, percentage of cells bearing receptors for the Fc portion of immunoglobulin (% FcR cells), killer (K) cell activity defined by antibody-dependent cellular cytotoxicity (ADCC), and natural killer (NK) cell activity. Central nervous system (CNS) immunoglobulin G (IgG) synthesis was also measured. The patients were followed carefully by both quantitative and qualitative methods for any change in their neurologic condition. Selective reduction in NK activity was observed with CY and 5-FU while no significant alteration was seen in %FcR cells and K activity. CY differed from 5-FU in reducing lymphocyte count and B cell percentage while 5-FU decreased the percentage of T cells. CCNU, but not the other drugs, reduced T cell proliferative response to PHA. In addition, CCNU, which is known to penetrate well into the nervous system, caused a modest reduction in CNS IgG synthesis, while 5-FU had an uncertain effect. Clinically the patients were unchanged or continued to progress in their disability. The results suggest an independence of the CNS immune from the systemic immune system in MS in response to many immunosuppressive drugs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603303      PMCID: PMC1535539     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals.

Authors:  J L Imbach; J L Montero; A Moruzzi; B Serrou; E Chenu; M Hayat; G Mathe
Journal:  Biomedicine       Date:  1975-12-20

Review 2.  The etiology and pathogenesis of multiple sclerosis: recent developments.

Authors:  C S Raine
Journal:  Pathobiol Annu       Date:  1977

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Mass spectrometric study of the distribution of cyclophosphamide in humans.

Authors:  J H Duncan; O M Colvin; C Fenselau
Journal:  Toxicol Appl Pharmacol       Date:  1973-02       Impact factor: 4.219

5.  Lymphocyte transformation induced in vitro by PHA and PPD in multiple sclerosis.

Authors:  W Cendrowski; K Niedzielska
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-02       Impact factor: 10.154

6.  Effect of anticancer chemotherapeutic agents on immune reactions of mice. I. Comparison of two nitrosoureas: 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.

Authors:  A Ghaffar; W Lichter; L L Wellham; M M Sigel
Journal:  J Natl Cancer Inst       Date:  1978-06       Impact factor: 13.506

7.  In vitro depression of human lymphocyte mitogen response (phytohaemagglutinin) by asbestos fibres.

Authors:  R G Barbers; W W Shih; A Saxon
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

8.  Comparison of immune derangements in patients with different malignancies.

Authors:  A Lichtenstein; J Zighelboim; F Dorey; S Brossman; J L Fahey
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

Review 9.  1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.

Authors:  S K Carter; F M Schabel; L E Broder; T P Johnston
Journal:  Adv Cancer Res       Date:  1972       Impact factor: 6.242

10.  The effect of immunopharmacological agents on mouse natural cell-mediated cytotoxicity and on its augmentation by poly I:C.

Authors:  J Y Djeu; J A Heinbaugh; W D Vieira; H T Holden; R B Herberman
Journal:  Immunopharmacology       Date:  1979-06
View more
  7 in total

1.  Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.

Authors:  Junjie Wu; David J Waxman
Journal:  Cancer Lett       Date:  2014-07-25       Impact factor: 8.679

2.  A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results.

Authors:  D A Compston; N M Milligan; P J Hughes; J Gibbs; V McBroom; B P Morgan; A K Campbell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-05       Impact factor: 10.154

3.  Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.

Authors:  L M Weiner; G R Hudes; J Kitson; J Walczak; P Watts; S Litwin; P J O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

4.  Multiple sclerosis intra-blood-brain-barrier IgG synthesis: effect of pulse intravenous and intrathecal corticosteroids.

Authors:  R W Baumhefner; W W Tourtellotte; K Syndulko; A Staugaitis; P Shapshak
Journal:  Ital J Neurol Sci       Date:  1989-02

5.  The effect of 5-fluorouracil/leucovorin chemotherapy on CpG methylation, or the confounding role of leukocyte heterogeneity: An illustration.

Authors:  Mathieu Lemire; Syed H E Zaidi; Brent W Zanke; Steven Gallinger; Thomas J Hudson; Sean P Cleary
Journal:  Genomics       Date:  2015-09-11       Impact factor: 5.736

6.  Increased spontaneous immunoglobulin secretion associated with cyclophosphamide-induced immune suppression.

Authors:  O Martínez-Maza; D J Moody; A R Rezai; G W Ellison; L W Myers; W W Tourtellotte; J L Fahey
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

Review 7.  Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Authors:  Mickael Bonnan
Journal:  Mult Scler Int       Date:  2015-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.